Chinese Titanium Refiner Ubridge Weighs $300 Million HK IPO
(Bloomberg) -- Guangdong Ubridge New Material Technology Co., a refiner of minerals including titanium and zirconium, is considering a Hong Kong initial public offering that could raise about $300 million, according to people familiar with the matter.
Most Read from Bloomberg
Subway Offers Free Sandwiches That Come With a Lifetime Commitment
Powell Has Stopped Handing Gifts to Wall Street on Fed Day
Fed Raises Interest Rates to 22-Year High, Leaves Door Open for More
Hunter Biden Plea Deal in Limbo After Judge Questions Terms
Mitch McConnell Freezes at Start of News Conference, Returns Later
The Maoming, Guangdong-based company has picked BNP Paribas SA and China Securities International to help arrange the first-time share sale, the people said. A listing could happen as soon as next year, said the people, who asked not to be identified as the information is private. The refiner is also exploring a funding round ahead of the IPO in order to bring in some strategic investors, the people said.
Considerations are preliminary and details of the fundraising including size and timeline could still change, the people said. A representative for Ubridge declined to comment, while representatives for BNP Paribas and China Securities International didn’t immediately respond to requests for comment.
Founded in 1989, Ubridge has more than 400 employees and an annual processing capacity of 300,000 tons for products including titanium ore, zircon sand and natural rutile, according to its website. It said it has started building long-term cooperation with overseas miners and looking for mines outside of China.
Most Read from Bloomberg Businessweek
Influencers Built Up This Wellness Startup—Until They Started Getting Sick
AI in Hollywood Has Gone From Contract Sticking Point to Existential Crisis
The Stainless-Steel Boom Is Tearing a South African Mining Region Apart
No Testing, No Inspections: Contaminated Eyedrops Blinded and Killed Americans
WeightWatchers Is Gambling Everything on Obesity Drugs
©2023 Bloomberg L.P.